Teva Pharma Industries Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.9816
- Today's High:
- $10.14
- Open Price:
- $10.05
- 52W Low:
- $7.09
- 52W High:
- $11.445
- Prev. Close:
- $10.04
- Volume:
- 12096780
Company Statistics
- Market Cap.:
- $10.78 billion
- Book Value:
- 6.293
- Revenue TTM:
- $15.02 billion
- Operating Margin TTM:
- 16.52%
- Gross Profit TTM:
- $6.97 billion
- Profit Margin:
- -14.88%
- Return on Assets TTM:
- 3.48%
- Return on Equity TTM:
- -26.58%
Company Profile
Teva Pharma Industries Ltd ADR had its IPO on 1990-03-26 under the ticker symbol TEVA.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Teva Pharma Industries Ltd ADR has a staff strength of 34,004 employees.
Stock update
Shares of Teva Pharma Industries Ltd ADR opened at $10.05 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.98 - $10.14, and closed at $10.03.
This is a -0.1% slip from the previous day's closing price.
A total volume of 12,096,780 shares were traded at the close of the day’s session.
In the last one week, shares of Teva Pharma Industries Ltd ADR have increased by +1.93%.
Teva Pharma Industries Ltd ADR's Key Ratios
Teva Pharma Industries Ltd ADR has a market cap of $10.78 billion, indicating a price to book ratio of 1.1731 and a price to sales ratio of 0.6493.
In the last 12-months Teva Pharma Industries Ltd ADR’s revenue was $15.02 billion with a gross profit of $6.97 billion and an EBITDA of $3.71 billion. The EBITDA ratio measures Teva Pharma Industries Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Teva Pharma Industries Ltd ADR’s operating margin was 16.52% while its return on assets stood at 3.48% with a return of equity of -26.58%.
In Q2, Teva Pharma Industries Ltd ADR’s quarterly earnings growth was a negative -80.8% while revenue growth was a positive 2.4%.
Teva Pharma Industries Ltd ADR’s PE and PEG Ratio
- Forward PE
- 3.6523
- Trailing PE
- 0
- PEG
- 0.755
Its diluted EPS in the last 12-months stands at $-1.98 per share while it has a forward price to earnings multiple of 3.6523 and a PEG multiple of 0.755. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Teva Pharma Industries Ltd ADR’s profitability.
Teva Pharma Industries Ltd ADR stock is trading at a EV to sales ratio of 1.9612 and a EV to EBITDA ratio of -2969.639. Its price to sales ratio in the trailing 12-months stood at 0.6493.
Teva Pharma Industries Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $43.10 billion
- Total Liabilities
- $11.84 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $119 million
- Dividend Payout Ratio
- 0%
Teva Pharma Industries Ltd ADR ended 2024 with $43.10 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $43.10 billion while shareholder equity stood at $7.05 billion.
Teva Pharma Industries Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $11.84 billion in other current liabilities, 57000000.00 in common stock, $-13950000000.00 in retained earnings and $17.12 billion in goodwill. Its cash balance stood at $2.67 billion and cash and short-term investments were $2.67 billion. The company’s total short-term debt was $1,980,000,000 while long-term debt stood at $18.70 billion.
Teva Pharma Industries Ltd ADR’s total current assets stands at $12.09 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.54 billion compared to accounts payable of $2.51 billion and inventory worth $4.11 billion.
In 2024, Teva Pharma Industries Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $119 million.
Comparatively, Teva Pharma Industries Ltd ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $10.03
- 52-Week High
- $11.445
- 52-Week Low
- $7.09
- Analyst Target Price
- $9.69
Teva Pharma Industries Ltd ADR stock is currently trading at $10.03 per share. It touched a 52-week high of $11.445 and a 52-week low of $11.445. Analysts tracking the stock have a 12-month average target price of $9.69.
Its 50-day moving average was $9.04 and 200-day moving average was $8.99 The short ratio stood at 1.89 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 4962.7% are held by institutions.
Frequently Asked Questions About Teva Pharma Industries Ltd ADR
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company’s products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.